Table 3.
Pathologic and Follow-up Data
HALN* | ON* | P Value | |
---|---|---|---|
Mean Follow-up mos (range) | 31.7 (8–47) | 51.0 (13–135) | <0.05 |
Pathologic Grade (%) | |||
Low (I and II) | 23 (60) | 33 (63) | 0.78 |
High (III) | 15 (40) | 19 (37) | |
Pathologic Stage (%) | |||
Superficial (Ta+Tis+T1) | 27 (71) | 41 (79) | 0.67 |
Invasive (T2+T3+T4) | 9 (29) | 11 (21) | |
Mean Interval to Recurrence (mos) | 7.7 | 9.1 | 0.55 |
Recurrence of TCC* (%) | |||
Bladder | 11 (29) | 18 (35) | 0.32 |
Contralateral ureter | 1 (3) | 2 (4) | |
Urethra | 1 (3) | 0 (0) | |
Metastatic | 2 (6) | 6 (11) | |
Current Disease Status* | |||
NED | 22 (58) | 23 (44) | 0.78 |
AWD | 14 (37) | 17 (33) | 0.69 |
DOD | 1 (3) | 9 (17) | 0.03 |
DWOD | 1 (3) | 3 (6) | 0.51 |
HALN=hand-assisted laparoscopic nephroureterectomy; ON= open nephroureterectomy; TCC=transitional cell carcinoma; NED=no evidence of disease; AWD=alive with disease; DOD=dead of disease; DWOD=dead without disease.